1. Home
  2. LOCO vs LCTX Comparison

LOCO vs LCTX Comparison

Compare LOCO & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo El Pollo Loco Holdings Inc.

LOCO

El Pollo Loco Holdings Inc.

HOLD

Current Price

$10.56

Market Cap

325.6M

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.63

Market Cap

366.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOCO
LCTX
Founded
1980
1990
Country
United States
United States
Employees
N/A
77
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
325.6M
366.2M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
LOCO
LCTX
Price
$10.56
$1.63
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$14.50
$4.67
AVG Volume (30 Days)
189.3K
958.5K
Earning Date
03-05-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
13.62
N/A
EPS
0.89
N/A
Revenue
$480,815,000.00
$10,816,000.00
Revenue This Year
$5.44
$6.32
Revenue Next Year
$1.64
$124.49
P/E Ratio
$12.08
N/A
Revenue Growth
2.09
24.05
52 Week Low
$8.29
$0.37
52 Week High
$12.65
$2.09

Technical Indicators

Market Signals
Indicator
LOCO
LCTX
Relative Strength Index (RSI) 42.96 46.09
Support Level $10.56 $1.58
Resistance Level $11.24 $1.71
Average True Range (ATR) 0.30 0.09
MACD -0.05 -0.01
Stochastic Oscillator 1.38 21.57

Price Performance

Historical Comparison
LOCO
LCTX

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: